Semaglutide vs Tirzepatide vs Retatrutide: Comparing Incretin Receptor Agonists for Laboratory Research

Semaglutide, tirzepatide and retatrutide are frequently grouped together in search results, supplier catalogues and internal procurement lists. They are not interchangeable. They differ in how many receptor pathways they are built to engage, how mature the published literature is for each, and – most practically for a laboratory – how you confirm which material you are actually holding.

This comparison sets out what each compound is studied in relation to, where the published evidence is thin, and what to check when specifying incretin receptor agonist research material. It is written for UK laboratory researchers and procurement teams working with research-use-only materials. It is not a guide to human use.

A quick orientation to the three receptor profiles

The incretin field is often described by the number of receptor pathways a compound is designed to engage.

Semaglutide is a long-acting GLP-1 receptor agonist. Much of the published work around it examines GLP-1 signalling in glucose regulation, gastric emptying, appetite-related pathways and cardiovascular outcomes. In the research context it is usually treated as the single-pathway comparator.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Dual incretin agonism is the feature that distinguishes it from a single-target GLP-1 compound. Research interest centres on combined GIP and GLP-1 signalling and how that differs from GLP-1 signalling alone.

Retatrutide is described as a triple receptor agonist, engaging GIP, GLP-1 and glucagon signals. It is the only triple agonist in the ADINA catalogue. Published work is at an earlier stage than for the other two, which matters when you are deciding how much weight to place on any single result.

Where the receptor labels help – and where they mislead

The single / dual / triple shorthand is useful for orientation, but it compresses a great deal. Three cautions are worth keeping in view.

First, a receptor profile is a description of intended pharmacology, not a specification of the material in front of you. A catalogue entry describing a triple agonist tells you what the compound is designed to engage; it does not by itself confirm the identity, quantity or purity of a given vial.

Second, more pathways does not automatically mean “better” or “stronger” in any research sense. It means a different set of questions. A researcher investigating GLP-1 signalling in isolation may specifically want a single-pathway compound so that the variable under study is not confounded by a second or third pathway.

Third, evidence maturity differs sharply between the three. Comparisons on this page reflect the state of published literature in general terms, not a claim about any individual study or about the performance of any particular supplier’s material.

What the literature covers, and where it thins

For single-pathway GLP-1 work, the literature is comparatively broad, with established research interest in glucose handling, gastrointestinal signalling and appetite regulation. That breadth makes single-agonist compounds a common reference point in study design.

For dual GIP/GLP-1 agonism, the published base is substantial and growing, and the central research question tends to be how combined receptor engagement compares with GLP-1 engagement alone. That is a genuinely different experimental question, and it is the main reason tirzepatide and semaglutide are not substitutes in a well-designed comparison.

For triple agonism, including glucagon signalling alongside GIP and GLP-1, the literature is newer and narrower. Researchers often describe this area as hypothesis-generating rather than settled. If you are building a study around a triple agonist, expect to justify the choice more fully and to treat any single finding as provisional.

Across all three, a recurring limitation is that much of the mechanistic work derives from laboratory and animal models. Findings from those models do not translate automatically to other systems, and the honest position is to state that boundary rather than work around it.

Telling the materials apart when specifying

Because the three compounds sit close together in catalogues, naming discipline matters. Practical steps that reduce specification errors:

• Record the full chemical name and any generic or catalogue name alongside the marketing name. ADINA lists compounds such as semaglutide and tirzepatide under their compound names and cross-references generic terminology, so it is worth capturing both on the requisition.
• State the receptor profile explicitly. Writing “dual GIP/GLP-1 agonist” or “triple agonist” on the request removes the ambiguity that a bare compound name can leave.
• Confirm the documentation status of the specific batch. A certificate of analysis or batch-specific document either exists for that material or it does not; if it is not yet available, treat it as pending rather than assumed.
• Use batch traceability information to tie a physical vial back to the record it was supplied with. For research-use-only materials, the link between the item and its paperwork is the part that matters at audit.
• Keep a copy of the specification you ordered against. When two compounds differ by a single word in a description, a stored specification is what lets you verify afterwards that you received what you intended.

A note on assessing supplier claims

Supplier pages for incretin agonists vary widely in how much they state and how carefully they distinguish research findings from product claims. Two habits help.

Read for the boundary. A well-written entry will tell you what a compound is studied in relation to and will stop short of asserting outcomes. Where a page makes human-use or weight-management claims, that is a signal to look more carefully at the rest of the listing.

Check what can actually be verified. Identity, declared quantity and documentation are checkable against batch records. Assertions about how a compound behaves in a living system generally are not, and should be traced to the primary literature rather than to marketing copy.

Choosing between them

If your study isolates GLP-1 signalling, a single-pathway compound is the natural comparator. If the question is how dual receptor engagement differs from GLP-1 alone, a dual agonist is required. If glucagon signalling is part of the hypothesis, a triple agonist is the only structure that fits – with the caveat that the evidence base is thinner and the design should reflect that.

In each case the decision should rest on the receptor profile and the experimental question, not on which compound appears most often in search results. Pair the choice with a specification you can trace and documentation you can verify.

For researchers building comparisons across the ADINA range, the relevant pages are Semaglutide, Tirzepatide and Retatrutide, alongside Retatrutide + Cagrilintide for combined-pathway research formulations.

All ADINA materials are supplied for laboratory and analytical research only. Where documentation for a specific batch is not yet available it is described as pending, and nothing on this page should be read as a claim about human use, dosing or therapeutic effect.